Publications 2011

Trancart S, Charreau I, Marchou M, Bocquentin M, Molina JM, Izopet J, Tangre P, Aboulker JP, Taburet AM, and ANRS 106 study group. Presence of Lamivudine or Emtricitabine is associated with reduced emergence of Nonnucleoside Reverse Transcriptase Inhibitor mutations in an Efavirenz-based intermittent antiretroviral treatment. Antimicrob Agents Chemother 2012, 56(3):1655 Lien PubMed

Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS,the PENPACT-1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial Original Text. The Lancet Infect Dis 2011, 11:273-83. Lien PubMed

Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, Ajana F, Colin de Verdière N, Reynes J, Foubert V, Roman F, Devaster JM, Delfraissy JF, and Aboulker JP, for the ANRS 151 Hifluvac study group and the french clinical vaccinology network (Réseau National d'Investigation Clinique en Vaccinologie REIVAC). Safety and immunogenicity of a monovalent 2009 influenza A/HIN1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011, 204:124-34.Lien PubMed

Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, De Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, and Molina JM on behalf of the EASIER ANRS 138 study group.Efficacy and Safety of Raltegravir in Treatment-Experienced HIV-1 Infected Patients Switching from Enfuvirtide-Based Regimens: 48-Week Results of the Randomized Easier - ANRS 138 Trial. J Antimicrob Chemother 2011, 66:2099-2106.Lien PubMed 

Goldwirt L, Braun J, de Castro N, Charreau I , Barrail-Tran A, Delaugerre C, Raffi F, Lascoux-Combe C, Aboulker JP, Taburet AM* and Molina JM.
Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a pharmacokinetic sub-study of the EASIER-ANRS 138 trial. Antimicrob Agents and Chemotherapy 2011, 55:3613-3615.Lien PubMed

Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM and Kuritzkes DR. Emerging Integrase Inhibitor Resistance Mutations in Raltegravir-Treated HIV-1-Infected Patients with Low-Level Viremia. AIDS 2011, 25:665-9.Lien PubMed
Tsatsaris V, Capitant C, Schmitz T, Chazallon C, Bulifon S, Riethmuller D, Picone O, Poulain P, Lewin F, Lainé F, Jacqz-Aigrain E, Aboulker JP, Launay O, for the Inserm C09-33 PREFLUVAC (Immunogenicity and Safety of an Inactivated Nonadjuvanted A[H1N1v] Influenza Vaccine in Pregnant Women) Study Group. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine. Ann Intern Med 2011, 155:733-741.Lien PubMed

Feeney ER,Chazallon C, O’Brien N, Meiffrédy V, Goodall RL, Aboulker JP, Cooper DA, Yeni P, Mallon PWG, on behalf of the INITIO Trial International Co-ordinating Committee. Hyperlactatemia in HIV-infected subjects initiating antiretroviral therapy in a large randomised study (a substudy of the INITIO trial). HIV Medicine Nov 2011, 12: 602-609. (* These authors equallycontributed to this work)Lien PubMed
Lutsar I, Trafojer UM, Heath PT, Metsvaht T, Standing J, Esposito S, de Cabre VM, Oeser C, Aboulker JP; NeoMero Consortium. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials. 2011 Sep 30;12:215.Lien PubMed  

Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D; ANRS 127 study group. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen. AIDS. 2011 Nov 13;25(17):2143-8. Lien PubMed
Gozalo C, Gérard L, Loiseau P, Morand-Joubert L, Peytavin G, Molina JM, Dellamonica P, Becquemont L, Aboulker JP, Launay O, Verstuyft C; ANRS 081 Study Group. Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):513-20. doi: 10.1111/j.1742-7843.2011.00780.x. Epub 2011 Sep 6.Lien PubMed 

Delobel P, Saliou A, Nicot F, Dubois M, Trancart S, Tangre P, Aboulker JP, Taburet AM, Molina JM, Massip P, Marchou B, Izopet J; ANRS 106-Window Study Team. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One. 2011;6(6):e21655. Epub 2011 Jun 27.Lien PubMed